LITS
Price:
$1.75
Market Cap:
$64.37M
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Industry
Biotechnology
IPO Date
2003-12-18
Stock Exchange
NASDAQ
Ticker
LITS
According to Lite Strategy, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.34. This represents a change of -60.18% compared to the average of -3.36 of the last 4 quarters.
The mean historical PE Ratio of Lite Strategy, Inc. over the last ten years is -0.46. The current -1.34 PE Ratio has changed 29.31% with respect to the historical average. Over the past ten years (40 quarters), LITS's PE Ratio was at its highest in in the June 2024 quarter at -0.41. The PE Ratio was at its lowest in in the September 2025 quarter at -4.90.
Average
-0.46
Median
-0.62
Minimum
-1.89
Maximum
1.70
Discovering the peaks and valleys of Lite Strategy, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 83.10%
Maximum Annual PE Ratio = 1.70
Minimum Annual Increase = -279.09%
Minimum Annual PE Ratio = -1.89
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -1.89 | -211.50% |
| 2024 | 1.70 | -279.09% |
| 2023 | -0.95 | 83.10% |
| 2022 | -0.52 | -16.07% |
The current PE Ratio of Lite Strategy, Inc. (LITS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-0.38
5-year avg
-0.46
10-year avg
-0.46
Lite Strategy, Inc.’s PE Ratio is less than TScan Therapeutics, Inc. (-1.03), less than Adicet Bio, Inc. (-0.43), less than Immunic, Inc. (-1.30), less than PMV Pharmaceuticals, Inc. (-0.82), greater than Relmada Therapeutics, Inc. (-1.96), greater than Nutriband Inc. (-5.53), less than Acrivon Therapeutics, Inc. Common Stock (-1.14), less than Werewolf Therapeutics, Inc. (-0.63), greater than XBiotech Inc. (-2.62), less than IO Biotech, Inc. (-0.51),
| Company | PE Ratio | Market cap |
|---|---|---|
| -1.03 | $61.86M | |
| -0.43 | $46.22M | |
| -1.30 | $67.93M | |
| -0.82 | $68.11M | |
| -1.96 | $293.33M | |
| -5.53 | $56.47M | |
| -1.14 | $76.05M | |
| -0.63 | $48.35M | |
| -2.62 | $76.52M | |
| -0.51 | $48.79M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lite Strategy, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lite Strategy, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Lite Strategy, Inc.'s PE Ratio?
How is the PE Ratio calculated for Lite Strategy, Inc. (LITS)?
What is the highest PE Ratio for Lite Strategy, Inc. (LITS)?
What is the 3-year average PE Ratio for Lite Strategy, Inc. (LITS)?
What is the 5-year average PE Ratio for Lite Strategy, Inc. (LITS)?
How does the current PE Ratio for Lite Strategy, Inc. (LITS) compare to its historical average?